New Frontiers in Selective Human MAO-B Inhibitors

Area of Science:

• Neuroscience
• Pharmacology
• Biochemistry

Background:

• Human monoamine oxidase-B (hMAO-B) is implicated in various neuropsychiatric and degenerative disorders.
• Conditions linked to hMAO-B include dementia, Parkinson's disease (PD), depression, schizophrenia, and alcoholism.

Purpose of the Study:

• To highlight the significance of hMAO-B as a therapeutic target.
• To review current strategies and challenges in developing selective hMAO-B inhibitors for disease treatment.

Main Methods:

• Review of existing literature on hMAO-B inhibitors.
• Analysis of various classes of synthetic and natural compounds targeting hMAO-B.
• Discussion of structural information limitations for rational drug design.

Main Results:

• Numerous compounds, including chalcones, pyrazoles, and coumarins, have been identified as potential hMAO-B inhibitors.
• Despite progress, structural insights into hMAO-B binding interactions remain insufficient for optimal drug design.

Conclusions:

• hMAO-B is a promising target for treating a wide spectrum of human diseases.
• Further research is needed to develop novel, potent, and selective hMAO-B inhibitors due to current limitations in structural understanding.